Browse the evidence

Obesity is a chronic, relapsing disease driven by disruptions in homeostatic, hedonic, and cognitive systems, rather than solely a lifestyle outcome, and requires multidisciplinary management including pharmacotherapy and surgery.

Treat obesity as a chronic disease, not a lifestyle failure. For eligible patients, GLP-1 agonists like semaglutide (2.4 mg weekly) combined with lifestyle changes produce significant weight loss (approx. 15%). Manage GI side effects with slow titration. Consider surgery for BMI ≥35.

Metabolic bariatric surgery is the most effective treatment for obesity across all BMI classes, offering durable weight loss and improvement in comorbidities.

For eligible patients (BMI ≥35, or 30-34.9 with failed lifestyle/pharma), metabolic bariatric surgery (sleeve or bypass) is the most effective treatment for durable weight loss and comorbidity improvement. It is recommended for BMI ≥35 regardless of comorbidities.

High-efficacy anti-obesity medications (AOMs) like semaglutide and tirzepatide produce significant weight loss in the majority of patients, but a subset of non-responders exists, and predictors of response or intolerance are currently unknown.

High-efficacy AOMs like semaglutide and tirzepatide work for most people, but not all. If you are a non-responder, it is not your fault, and current science cannot yet predict who will respond. Discuss alternative strategies or phenotypes with your provider.

GLP-1 receptor agonists (semaglutide 2.4 mg) and dual GIP/GLP-1 agonists (tirzepatide) reduce major adverse cardiovascular events (MACE) in obese patients without diabetes, independent of weight loss alone.

If you are obese and have existing heart disease, ask your doctor about GLP-1 agonists like semaglutide. They significantly lower your risk of heart attack and stroke, offering protection beyond just weight loss.

GLP-1 and GIP/GLP-1 agonists improve heart failure with preserved ejection fraction (HFpEF) symptoms and functional capacity in obese patients, independent of diabetes status.

If you have obesity and heart failure with preserved ejection fraction, discuss GLP-1 agonists with your cardiologist. They can significantly improve your heart failure symptoms, exercise capacity, and quality of life.

GLP-1 and GIP receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease, independent of weight loss magnitude.

For patients with type 2 diabetes and existing heart disease, GLP-1 therapies like liraglutide and semaglutide significantly reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death). This benefit exists alongside weight loss and may be partly due to direct protective effects on the heart and blood vessels. These drugs are now a standard part of care for high-risk diabetic patients.

Osteosarcopenia is defined by the simultaneous loss of muscle mass, muscle strength, bone mass, and functional capacity, and is associated with significantly higher risks of falls, fractures, and mortality compared to having either condition alone.

Osteosarcopenia is the dangerous combination of weak muscles and weak bones. It significantly increases your risk of falls, fractures, and death compared to having just one of these conditions. A comprehensive assessment should check both muscle and bone health.

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce cardiovascular death, heart failure hospitalizations, and renal composite outcomes in patients with type 2 diabetes and chronic kidney disease, regardless of baseline glycemic control.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors like empagliflozin or dapagliflozin. These medications are proven to significantly lower your risk of heart failure, kidney failure, and death, offering protection beyond just blood sugar control.

GLP-1 receptor agonists (liraglutide, semaglutide) reduce major adverse cardiovascular events (MACE) and nephropathy progression in high-risk patients with Type 2 Diabetes.

For those with Type 2 Diabetes and high heart risk, GLP-1 agonists like liraglutide or semaglutide offer strong protection against heart attacks and strokes, as well as kidney damage. Discuss these options with your doctor, especially if you are overweight.

SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) significantly reduce cardiovascular mortality and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.

If you have Type 2 Diabetes and heart disease or high risk, ask your doctor about SGLT-2 inhibitors (like empagliflozin or dapagliflozin). These drugs protect your heart and kidneys beyond just lowering blood sugar, significantly reducing the risk of heart failure hospitalization and death. Be aware of potential side effects like infections, but discuss how the heart benefits may outweigh these risks for your specific health profile.

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce Major Adverse Cardiovascular Events (MACE) and all-cause mortality in patients with Type 2 Diabetes and established CVD, primarily through weight loss, blood pressure reduction, and anti-inflammatory effects.

If you have Type 2 Diabetes and heart disease, GLP-1 agonists (like semaglutide or liraglutide) are highly effective at reducing the risk of heart attacks, strokes, and death. They work by mimicking a gut hormone to lower blood sugar, promote weight loss, and reduce blood pressure. While they require injections and may cause temporary stomach issues, the heart protection benefits are substantial and well-documented.

Obesity increases the risk of various cancers (e.g., breast, colorectal, liver) through mechanisms involving chronic inflammation, oxidative stress, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin).

Obesity increases your risk for several types of cancer through biological processes like inflammation and hormone imbalance. Maintaining a healthy weight can reduce this risk by mitigating these specific biological factors.

Obesity contributes to cardiovascular disease (CVD) through mechanisms including adipose tissue dysfunction, ectopic fat deposition, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin), leading to hypertension, atherosclerosis, and heart failure.

Obesity increases your risk for heart disease and stroke through biological processes like inflammation and hormone imbalance. Maintaining a healthy weight can reduce this risk by mitigating these specific biological factors.

Obesity is a primary driver of Heart Failure with Preserved Ejection Fraction (HFpEF) through cardiometabolic mechanisms including systemic inflammation, lipotoxicity, and metabolic remodeling, rather than being merely a comorbidity.

If you have HFpEF and obesity, your body's metabolism and inflammation are likely driving your heart condition. This is not just about 'being overweight' but involves complex biological changes like fat toxicity and inflammation. Managing obesity through weight loss interventions (like GLP-1 agonists or lifestyle changes) can target these root causes and improve heart health.

Discontinuation of semaglutide or tirzepatide leads to significant weight regain, indicating that these therapies require long-term use to maintain metabolic benefits.

If you stop taking semaglutide or tirzepatide, you will likely regain most of the weight you lost. These drugs treat obesity and diabetes as chronic conditions, meaning they are meant to be taken long-term to maintain the health benefits. Stopping them reverses the progress made.

Long-term weight loss (2 years) is equivalent across diets emphasizing different macronutrients (low/high fat, average/high protein, low/high carbohydrate) when caloric intake is reduced and adherence is supported.

To lose weight, focus on creating a consistent caloric deficit rather than obsessing over whether your diet is high-protein, low-carb, or low-fat. This study shows that if you can adhere to a reduced-calorie diet (approx. 750 kcal deficit/day) for two years, you will lose a similar amount of weight regardless of the macronutrient breakdown. Use behavioral tools like food diaries and regular check-ins to maintain adherence, as attendance and consistency were the strongest predictors of success.

While weight loss is similar across macronutrient groups, specific diets produce distinct improvements in cardiovascular risk factors (e.g., LDL, HDL, Triglycerides).

If you have high cholesterol or cardiovascular risk, choose a diet that aligns with your specific biomarkers. Low-fat/high-carb diets tend to lower LDL (bad cholesterol) more effectively, while high-fat/low-carb diets may raise HDL (good cholesterol) more. Since weight loss is similar across all, use your lipid profile to guide your macronutrient choice.

Intensive lifestyle intervention improves cardiovascular risk factors including fitness, HbA1c, systolic blood pressure, and HDL-C levels in individuals with type 2 diabetes, but does not significantly improve LDL-C levels compared to usual care when medication use is accounted for.

While lifestyle changes improve many heart health markers, they may not lower LDL cholesterol as effectively as medications for some individuals. It is important to discuss lipid management with a healthcare provider, as medication might be necessary to achieve LDL goals.

A 12-month healthy low-carbohydrate diet and a healthy low-fat diet produce statistically equivalent weight loss in overweight adults, with no significant difference between the two approaches.

For overweight adults, both a healthy low-fat diet and a healthy low-carbohydrate diet lead to similar weight loss over 12 months. The specific macronutrient ratio matters less than the quality of food (whole foods, minimal processing) and the ability to adhere to the diet long-term. You do not need genetic testing or insulin measurements to choose between them; pick the one you can sustain.

When combined with comprehensive behavioral treatment, low-carbohydrate and low-fat diets produce equivalent long-term weight loss (approx. 7% at 2 years), refuting the claim that low-carb diets are superior for long-term weight loss.

If you are struggling to lose weight long-term, the specific type of diet (low-carb vs. low-fat) matters less than your ability to stick to it. This study shows that with proper behavioral support (tracking, counseling, exercise), both diets lead to similar, significant weight loss (around 7% of body weight) over two years. Focus on building sustainable habits rather than searching for a 'magic' macronutrient ratio.

A low-carbohydrate diet is associated with greater reductions in triglycerides and VLDL cholesterol in the first 6 months compared to a low-fat diet, but these differences diminish by 2 years.

If you start a low-carb diet, you may see a quick improvement in triglycerides and VLDL cholesterol within the first 6 months. However, as you gradually increase carbohydrates over the year, this specific benefit may fade. It is still a positive early marker, but not a permanent differentiator from low-fat diets.

Rapid weight loss via a low-energy diet (810 kcal/day for 8 weeks) induces gender-specific metabolic adaptations: men lose more total body weight and fat mass with greater improvements in metabolic syndrome Z-score, whereas women lose relatively more fat-free mass and experience larger reductions in HDL cholesterol and hip circumference, despite similar improvements in insulin resistance.

If you are using a very low-calorie diet (around 800 kcal/day) to jumpstart weight loss, expect different results based on your sex. Men will likely lose more total weight and fat, with better improvements in overall metabolic risk. Women may lose less total weight but will still improve insulin resistance. However, women should be aware that this specific rapid loss phase may lead to greater loss of lean muscle and a drop in 'good' cholesterol (HDL). This doesn't mean the diet is 'bad' for women, but it highlights the need for careful monitoring and a strong focus on preserving muscle mass (via protein and resistance training) once you transition to a maintenance diet.

Low carbohydrate diets are not significantly superior to low fat diets for weight loss when protein content is held constant.

You do not need to choose between low-carb and low-fat based on efficacy; both work equally well if you stick to them. Focus on adherence and protein intake rather than eliminating entire food groups, as no single diet is superior.

During the initial phase of severe caloric restriction, the majority of rapid body weight loss is due to water loss rather than fat or protein oxidation, resulting in a significantly lower caloric equivalent per kg of weight lost.

When you start a strict low-calorie diet, expect to lose weight faster than your calorie math predicts in the first week. This is largely water, not just fat. Do not be discouraged if the rate slows down after the first few days; the fat loss rate is likely more constant than the total weight loss suggests.